Chinese biotech firm WuXi AppTec Co. has become a top short target as its significant stock rally, which saw an 80% increase this year, begins to attract a growing number of skeptics.

A US judge on Friday barred the Defense Department from including Chinese biotechnology company WuXi AppTec Co on a list of companies believed to support Beijing's military. The judge stated that the government lacked sufficient evidence to justify the decision.

WuXi AppTec has announced its financial results, reporting a Non-GAAP EPS of $3.92 and total revenue of $28.9 million.

ClearBridge International Growth Strategy added ABB and BUD while exiting SAP and Wuxi AppTec in Q2. Separately, the ClearBridge Global Infrastructure Income Strategy added DTM and exited PEG, MAQAF, and SSEZF during the same quarter.

Analysts suggest that the Pentagon's blacklisting of Chinese pharmaceutical contractor WuXi AppTec, citing alleged military ties, will not deter multinational drug makers from collaborating with China's biopharmaceutical industry due to cost benefits.

WuXi AppTec has released its financial performance figures for the first quarter of the year.

WuXi AppTec Co.'s stock has seen a 100% rally, defying geopolitical challenges including its designation as a Chinese military company by the Pentagon.

A US federal judge has temporarily blocked the Pentagon from designating Chinese biotechnology group WuXi AppTec as a 'Chinese military company', finding that defense officials repeatedly misread the evidence.

Chinese biotech giant Wuxi AppTec, Asia’s largest contract pharmaceutical research provider, exceeded market expectations with a surge in net income for the first half of the year. This growth was fueled by high demand for weight-loss and diabetes drugs, alongside gains in its US business, despite ongoing US scrutiny.

A Chinese biotechnology company, WuXi AppTec, has filed a lawsuit against the US government after being placed on a list of businesses linked to China's military by the US Department of Defense.

Chinese contract drug makers – including WuXi AppTec, WuXi Biologics and WuXi XDC – face a less certain long-term revenue outlook as US pharmaceutical companies bring production in-house and reconfigure supply chains amid rising US-China tensions. While near-term earnings remained largely locked in, visibility beyond that was limited, according to Cui Cui, head of healthcare research for Asia at Jefferies. “Earnings visibility for 2026 and 2027 is still very strong – revenue momentum is large...

A US judge has temporarily blocked the Defense Department from enforcing its designation of WuXi AppTec Co. as a Chinese military company. This grants temporary relief to the major pharmaceutical contractor amidst ongoing scrutiny.

Wuxi Apptec reported an earnings beat and raised its full-year guidance, leading Jefferies' Head of Asia Healthcare Research, Cui Cui, to maintain a bright outlook for the company.

WuXi AppTec has filed a complaint against the U.S. Department of Defense, challenging the department's decision to link the company to the Chinese military.

Chinese drug maker WuXi AppTec announced record first-quarter revenue, driven by a robust order backlog and sustained demand from pharmaceutical companies worldwide. The company's growth was supported by its strong global market presence.